mRNA Cancer Vaccine Cuts Melanoma Recurrence in 1,137 Patients

A personalized mRNA vaccine combined with immunotherapy slashed skin cancer recurrence rates in over 1,000 high-risk melanoma patients.

It's the first late-stage trial success for mRNA cancer treatment, opening new hope for patients worldwide.